Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- IH +7.8% (announces third quarter 2025 unaudited financial results)
Other news:
-
ANL +25% (enters exclusive license agreement with ASK Pharm for Pan-RAS inhibitor AN9025 in greater China)
-
PRAX +12.7% (announces the FDA has granted breakthrough therapy designation for ulixacaltamide HCl in essential tremor)
-
LOT +7.6% (announces $23 million strategic investment from ECARX (ECX))
-
CANG +4.3% ( sole shareholder of Class B shares Enduring Wealth Capital Limited decided to increase its investment in the Company by subscribing for additional Class B ordinary shares of the Company in cash)
-
UUUU +3.1% (announced it has exceeded previously disclosed guidance for finished uranium production, mined uranium ore production, and uranium concentrate sales for FY25)
-
CPNG +3% (plans to implement a 1.685 trillion won customer compensation plan to restore customer trust)
-
UNCY +1.6% ( has resubmitted its New Drug Application to the U.S. FDA for oxylanthanum carbonate, its investigational oral phosphate binder for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis )
-
NVO +1.5% (lowers price of Wegovy in some Chinese provinces by 50%, according to Bloomberg)
-
ALV +1.4% (announced that Fredrik Westin has agreed with the Company to amend his resignation date to be effective March 31, 2026)
-
EC +1.2% (assumes 100% interest in offshore blocks in the Southern Caribbean, also confirms that on Friday, December 19, 2025, the Unión Sindical Obrera started the early collective bargaining process with the Company )
- GLSI +1.1% ( extends lock-up of directors and officers to September 30, 2026)